| scholarly article | Q13442814 |
| P2093 | author name string | Lisa A Carey | |
| Dominic T Moore | |||
| Mark Graham | |||
| David W Ollila | |||
| William G Cance | |||
| Benjamin F Calvo | |||
| Julian Rosenman | |||
| Lynda Sawyer | |||
| Carolyn Sartor | |||
| P2860 | cites work | Treatment of large and locally advanced breast cancers using neoadjuvant chemotherapy | Q74355036 |
| Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonié Bordeaux Groupe Sein (IBBGS) | Q74604115 | ||
| Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy | Q74611825 | ||
| Effect of preoperative chemotherapy on the outcome of women with operable breast cancer | Q77093352 | ||
| Neoadjuvant chemotherapy in the treatment of stage II and III breast cancer | Q77224816 | ||
| Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience | Q31826495 | ||
| Preoperative (neoadjuvant) chemotherapy in patients with breast cancer | Q34333017 | ||
| Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy | Q39540808 | ||
| Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. | Q40675977 | ||
| Surgical conservation planning after neoadjuvant chemotherapy for stage II and operable stage III breast carcinoma | Q42171964 | ||
| Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel | Q43918762 | ||
| Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases. | Q54319990 | ||
| Effect of surgical removal on the growth and kinetics of residual tumor | Q66921894 | ||
| Results of a conservative treatment combining induction (neoadjuvant) and consolidation chemotherapy, hormonotherapy, and external and interstitial irradiation in 98 patients with locally advanced breast cancer (IIIA-IIIB) | Q70385253 | ||
| T3b-T4 breast cancer: factors affecting results in combined modality treatments | Q70422624 | ||
| Possibility of conservative local treatment after combined chemotherapy and preoperative irradiation for locally advanced noninflammatory breast cancer | Q70997885 | ||
| Conservation surgery after primary chemotherapy in large carcinomas of the breast | Q71558092 | ||
| Embolization coils as tumor markers for mammography in patients undergoing neoadjuvant chemotherapy for carcinoma of the breast | Q73339961 | ||
| Primary chemotherapy and preoperative irradiation for patients with stage II larger than 3 cm or locally advanced non-inflammatory breast cancer | Q73346648 | ||
| The feasibility of minimally invasive surgery for stage IIA, IIB, and IIIA breast carcinoma patients after tumor downstaging with induction chemotherapy | Q73549642 | ||
| Breast conservation and prolonged chemotherapy for locally advanced breast cancer: the University of Michigan experience | Q73585192 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | breast carcinoma | Q18555947 |
| P304 | page(s) | 295-302; discussion 302-3 | |
| P577 | publication date | 2002-09-01 | |
| P1433 | published in | Annals of Surgery | Q4767866 |
| P1476 | title | Long-term outcome of neoadjuvant therapy for locally advanced breast carcinoma: effective clinical downstaging allows breast preservation and predicts outstanding local control and survival | |
| P478 | volume | 236 |
| Q35657487 | Accuracy of ultrasonography and mammography in predicting pathologic response after neoadjuvant chemotherapy for breast cancer |
| Q36169992 | Breast conservation in locally advanced breast cancer |
| Q38253593 | Breast conservation in the setting of contemporary multimodality treatment provides excellent outcomes for patients with occult primary breast cancer. |
| Q38452286 | Breast-conserving surgery after tumor downstaging by neoadjuvant chemotherapy is oncologically safe for stage III breast cancer patients |
| Q37697506 | Breast-conserving surgery in locally advanced breast cancer submitted to neoadjuvant chemotherapy. Safety and effectiveness based on ipsilateral breast tumor recurrence and long-term follow-up |
| Q37055326 | CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel |
| Q98386324 | Clinical value and application of contrast-enhanced ultrasound in the differential diagnosis of malignant and benign breast lesions |
| Q46429749 | Comparison of breast-conserving surgery with mastectomy in locally advanced breast cancer after good response to neoadjuvant chemotherapy: A PRISMA-compliant systematic review and meta-analysis |
| Q37301839 | DEGRO practical guidelines: radiotherapy of breast cancer I: radiotherapy following breast conserving therapy for invasive breast cancer |
| Q37701896 | Distinct pathways regulated by RET and estrogen receptor in luminal breast cancer demonstrate the biological basis for combination therapy. |
| Q99569593 | Effect of pathologic stages on postmastectomy radiation therapy in breast cancer receiving neoadjuvant chemotherapy and total mastectomy: A Cancer Database Analysis |
| Q36917231 | Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer |
| Q47103183 | Evaluation of Surgical Outcomes of Oncoplasty Breast Surgery in Locally Advanced Breast Cancer and Comparison with Conventional Breast Conservation Surgery |
| Q34293229 | Expression of multidrug resistance proteins in invasive ductal carcinoma of the breast |
| Q28270514 | Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944) |
| Q37288041 | High TFAP2C/low CD44 expression is associated with an increased rate of pathologic complete response following neoadjuvant chemotherapy in breast cancer. |
| Q30981785 | Hyperthermia Is Now Included in the NCCN Clinical Practice Guidelines for Breast Cancer Recurrences: An Analysis of Existing Data |
| Q42485941 | Impact of breast cancer molecular subtypes on locoregional recurrence in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer |
| Q89302625 | Impact of receptor phenotype on nodal burden in patients with breast cancer who have undergone neoadjuvant chemotherapy |
| Q39030146 | Local Recurrence after Breast-Conserving Surgery and Mastectomy Following Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer - a Meta-Analysis |
| Q35000874 | Local recurrence rates are low in high-risk neoadjuvant breast cancer in the I-SPY 1 Trial (CALGB 150007/150012; ACRIN 6657) |
| Q36546612 | Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice |
| Q35728692 | Management of local recurrence of breast cancer |
| Q44354897 | Measurement of volumetric and vascular changes with dynamic contrast enhanced MRI for cancer therapy monitoring |
| Q47239440 | Noninflammatory breast carcinoma with skin involvement |
| Q51064316 | Oncologic progression of patients with advanced breast carcinoma undergoing immediate breast reconstruction. |
| Q47101783 | Oncological outcome of complete response after neoadjuvant chemotherapy for breast conserving surgery: a systematic review and meta-analysis |
| Q33973166 | Oncoplastic technique in breast conservative surgery for locally advanced breast cancer |
| Q37701817 | Osteonecrosis of the jaw associated with everolimus: A case report |
| Q34368298 | Outcome of neoadjuvant chemotherapy in locally advanced breast cancer: A tertiary care centre experience |
| Q51808443 | Outcomes and predictive factors for salvage therapy after local--regional recurrence following neoadjuvant chemotherapy and breast conserving therapy. |
| Q46143861 | Pre-operative Endocrine Therapy |
| Q38832422 | Predicting breast cancer response to neoadjuvant chemotherapy using pretreatment diffuse optical spectroscopic texture analysis |
| Q24812541 | Predictors of primary breast cancers responsiveness to preoperative epirubicin/cyclophosphamide-based chemotherapy: translation of microarray data into clinically useful predictive signatures |
| Q36848102 | Preoperative concurrent paclitaxel-radiation in locally advanced breast cancer: pathologic response correlates with five-year overall survival |
| Q51017227 | Proliferation rate and breast cancer subtype, but not ALDH1 expression, predict pathological response to neoadjuvant chemotherapy in locally advanced breast cancer. |
| Q25257743 | Quantification of the response of circulating epithelial cells to neodadjuvant treatment for breast cancer: a new tool for therapy monitoring |
| Q88556990 | Risk factors for locoregional disease recurrence after breast-conserving therapy in patients with breast cancer treated with neoadjuvant chemotherapy: An international collaboration and individual patient meta-analysis |
| Q35638695 | Staging of breast cancer in the neoadjuvant setting |
| Q37244111 | State of the art of neoadjuvant chemotherapy in breast cancer: rationale, results and recent developments |
| Q43457976 | The integrated evaluation of the results of oncoplastic surgery for locally advanced breast cancer |
| Q36816914 | The response to neoadjuvant chemotherapy predicts clinical outcome and increases breast conservation in advanced breast cancer |
| Q37171652 | The role of oncoplastic breast conserving treatment for locally advanced breast tumors. A matching case-control study |
| Q79969459 | The safety of breast-conserving surgery in patients who achieve a complete pathologic response after neoadjuvant chemotherapy |
| Q35985784 | Tissue and Serum miRNA Profile in Locally Advanced Breast Cancer (LABC) in Response to Neo-Adjuvant Chemotherapy (NAC) Treatment |
| Q34158197 | Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial. |
| Q34206297 | Young women with locally advanced breast cancer who achieve breast conservation after neoadjuvant chemotherapy have a low local recurrence rate |
Search more.